Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

Scios  Acquired by JohnsonAndJohnson (2003 $ 2,400,000,000)

6500 Paseo Padre Parkway
Fremont, CA 94555
USA
(408)-248-2500
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) Steven D. Goldby (Venrock Associates Partner) Sam Armacost (Bank of America President);  Randal Kirk (Third Security Managing Director);  Donald Rice (UroGenesys CEO);  Charles Sanders (Squibb Division CEO);  Solomon Snyder (Johns Hopkins University Neuroscience Department);  Burton Sobel (University of Vermont College of Medicine);  Eugene Step (Eli Lilly)
Company

Business description: Scios developed and markets Natrecor® (nesiritide), the first new treatment for acute heart failure in more than a decade. Scios has a growing pipeline, including SCIO-469 and SCIO-323, of oral p38 kinase inhibitors in clinical trials. SCIO-469 is being studied for the potential treatment of rheumatoid arthritis (RA). Scios’ disease-based technology platform integrates expertise in protein biology with computational and medicinal chemistry to design small molecule compounds for large markets with unmet medical needs. Scios also is advancing small-molecule inhibitors of TGF-beta through preclinical development. Scios' research effort is focused on diseases of the cardiovascular system, with a particular emphasis on inflammation and scarring. Scios has emphasized an emerging family of protein therapeutic targets: kinases. By applying advanced technologies with proprietary methodology, Scios is working to identify kinases active in diseases within its strategic focus and developing and testing inhibitors of those enzymes for potential therapeutic value. SCIO-469 and the emerging TGF-beta program represent the success of this innovative approach.
Partners include: GenentechMerckPfizer;  Bayer AG;  Kaken Pharmaceutical;  Marion Merrell Dow
Capital

Ownership: Acquired by JohnsonAndJohnson (2003 $ 2,400,000,000)
Corporate investors: MerckJohnsonAndJohnson

Last Tweets


 

Last Mentions


Overview
Record updated: Sep 2005
Sector: Biotech
Year Founded: 1981
Headcount: 701-800 as of Dec 2004
Ownership: Acquired by JohnsonAndJohnson (2003 $ 2,400,000,000)